CLX|Analyst Targets
CLX|Company Info
CLX|Insider Trading
CLX|Fundamentals
CLX|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $1.35 | - | - |
| Q1'27 | $1.08 | $1.55 | +44.1% |
| Q4'26 | $1.65 | $1.66 | +0.9% |
| Q3'26 | $1.55 | $1.64 | +6.1% |
| Q2'26 | $1.57 | $1.39 | -11.5% |
| Q3'25 | $0.78 | $0.85 | +9.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $1.9B | - | - |
| Q1'27 | $1.9B | $1.9B | +0.5% |
| Q4'26 | $1.9B | $1.9B | +1.6% |
| Q3'26 | $1.7B | $1.7B | +0.1% |
| Q2'26 | $1.7B | $1.7B | +0.0% |
| Q3'25 | - | $1.4B | - |
CLX|Monthly Returns
Market Data
CLX Stock Snapshot
- Market cap
- 12.01B
- P/E ratio
- 17.7
- Day range
- $96.19 – $99.29
- News sentiment
- 51/100 · Neutral
- Analyst target
- $98.65 (+1.6%)
- Consensus
- Hold · 28 analysts
Price action on CLX is defensive - rallies are being sold rather than extended. In Consumer Defensive, names this size usually take direction from sector flows before company-level news.
Reverse DCF
What growth is priced into CLX?
At today's price, The Clorox Company needs to grow free cash flow about -4.4% a year for 3 years, slowing to a long-run rate by year 10, to justify its valuation at a 6.20% cost of capital. Over the last five years its revenue has trended at -0.7% a year, so the market is asking for 3.8 percentage points below its own delivered rate. On that basis CLX looks priced below what its own growth record supports.
- Implied FCF growth
- -4.4%
- Growth trend
- -0.7%
- Growth gap
- -3.8 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 6.20%
- Beta
- 0.48
Behaviour On Record
What CLX's own history says about today's numbers
- Realized volatility (21d)
- 33.5% 91st pct
- Below its peak
- -57.7%
- vs 200-day average
- +1.4%
- Up days (1y)
- 47%
The Clorox Company is currently running 33.5% annualised volatility over the last 21 sessions. Measured against CLX's own 13 years of daily returns rather than a market-wide average, that is the 91st percentile — an extreme by its own standards, against a typical reading of 19.5%.
CLX is trading -57.7% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -20.4%, and the deepest was -40.1% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.
Price sits +1.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 51st percentile — close to the gap it normally carries. Over the past year CLX closed higher on 47% of sessions, and it is currently 4 sessions into a rising streak.
On November specifically: over 13 years of records, CLX finished the month higher 8 of 13 times, with a median return of +1.1% and an average of +1.5%. Its strongest month historically has been June at +2.0% on average, its weakest September at -3.4%.
Overnight risk is measurable too: CLX has opened more than 2% away from the prior close in 53 of 3,268 sessions (1.6% of the time), with the largest gaps running +5.9% and -5.0%.
Across the last 4 dated reports on file, CLX moved an average of 4.4% in the session after earnings, closing higher 3 of those 4 times, with a median move of +4.7% and a largest of +5.8%.
All figures computed from 3,269 daily closes between 2013-11-06 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against CLX's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of CLX's sector?
The Clorox Company sits in the Consumer Staples sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (weakening).
- Sector rank
- #2 of 12
- Sector state
- Weakening
- Sector rotation score
- 73
Analyst Consensus Estimates
What do analysts expect CLX to earn?
Analysts expect The Clorox Company to earn $5.70 per share in the fiscal year ending Jun 2027 and $6.40 in the fiscal year ending Jun 2029, from 3 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.
Analyst Rating Changes
Are analysts turning bullish or bearish on CLX?
Morgan Stanley most recently reiterated its rating on The Clorox Company to Equal-Weight on Nov 4, 2026 with a price target of $94 (from $87). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- Morgan Stanley: Equal-Weight
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
Earnings Release, Scored
What did The Clorox Company's latest earnings release say?
Most important lines
- 1
Net sales increased 33% to $1.91 billion.
New this quarter - 2
Net sales increased 11%.
New this quarter - 3
Adjusted EPS growth rate reflects the impact of lapping the ERP transition-related inventory drawdown in the year-ago quarter, which was about 90 cents.
New this quarter
Peers & ETF holders
CLX peers & ETF holders
Household & Personal ProductsMarket cap · today
News & sentiment
What is the news saying about CLX?
CLX rose 16.1% over the month to Nov 6. News tone held between 30 and 100 from Oct 6 to Oct 23, then dropped to 31 on Oct 26.
- Oct 22 +4.5%
- Nov 2 +5.0%same day: ADRNY or CLX: Which Is the Better Value Stock Right Now?
- Nov 4 +5.7%same day: ETFs Are Net Sellers of Clorox (CLX) on Nov. 2
Technical analysis
How strong is CLX's momentum right now?
On the daily chart CLX ranks at the 14th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.
Institutional ownership
Are big funds buying or selling CLX?
86 of the 185 tracked managers added to CLX in their latest 13F and 97 trimmed. Together they own 69.5% of the company, worth $8.1B. BlackRock and State Street alone hold 15.0%.
- 1BlackRock, Inc.8.15%$958.6M positionTrimmed 1.3% last quarter
- 2State Street Corp6.84%$804.8M positionAdded 2.2% last quarter
- $753.6M positionAdded 0.6% last quarter
- 4Invesco Ltd.4.88%$573.6M positionAdded 23.7% last quarter
- $553.5M positionAdded 0.3% last quarter
- $310.4M positionAdded 1.1% last quarter
- 7Van Eck Associates Corp2.41%$283.7M positionTrimmed 7.6% last quarter
- 8Morgan Stanley1.82%$214.4M positionTrimmed 17.3% last quarter
- $197.8M positionAdded 199.6% last quarter
- 10UBS Group AG1.61%$189.0M positionAdded 116.6% last quarter
Congressional trading
Is Congress trading CLX?
7 members of Congress disclosed 25 CLX trades between Feb 19, 2014 and May 15, 2026: 11 buys and 14 sells, about $650.0K in estimated value.
What stands out
Click one to highlight its trades in the chartDiscover more
How has CLX done against its peers?
Over the six months to Nov 6, CLX returned +8.1%. Of the 7 related stocks, 6 did better, led by EL at +23.4%.
- 1ELThe Estée Lauder Companies Inc.up 23.4%+15.2 pts
- 2PMPhilip Morris International Inc.up 15.2%+7.1 pts
- 3CHDChurch & Dwight Co., Inc.up 13.7%+5.6 pts
- 4PGThe Procter & Gamble Companyup 10.2%+2.1 pts
- 5KMBKimberly-Clark Corporationup 8.7%+0.6 pts
- 6CLColgate-Palmolive Companyup 8.4%+0.3 pts
- 7CLXThis stockup 8.1%
- 8MOAltria Group, Inc.up 7.7%−0.5 pts